Prefrontal cortical and striatal transcriptional responses to the reinforcing effect of repeated methylphenidate treatment in the spontaneously hypertensive rat, animal model of attention-deficit/hyperactivity disorder (ADHD)

Behavioral and Brain Functions

Volumn 10, Issue 1, 2014, Pages

  dela Peña, Ike ^a   Kim, Hee J ^a   Sohn, Aeree ^a   Kim, Bung Nyun ^b   Han, Doug H ^c   Ryu, Jong H ^d   Shin, Chan Y ^e   Noh, Minsoo ^f   Cheong, Jae H ^a  

^a Sahmyook University   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Chung Ang University College of Medicine   (South Korea)

^d Kyung Hee University   (South Korea)

^e Konkuk University School of Medicine   (South Korea)

^f Seoul National University   (South Korea)

Author keywords

Addiction; ADHD; Gene expression; Methylphenidate

Indexed keywords

ALKALINE CERAMIDASE 2; ANGIOPOIETIN LIKE 4; CALGRANULIN B; CCAAT ENHANCER BINDING PROTEIN BETA; CONNECTIVE TISSUE GROWTH FACTOR; ELONGATION FACTOR 2 KINASE; GUANINE NUCLEOTIDE BINDING PROTEIN; HEMOGLOBIN ALPHA CHAIN; I KAPPA B KINASE ALPHA; JUNCTIONAL ADHESION MOLECULE B; METALLOTHIONEIN I; METHYLPHENIDATE; NOTCH3 RECEPTOR; PREALBUMIN; PROTEIN HOMER 1; TRANSIENT RECEPTOR POTENTIAL CHANNEL A1; UBIQUITIN PROTEIN LIGASE NEDD4; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATTENTION DEFICIT DISORDER; CELL ADHESION; CONDITIONED PLACE PREFERENCE TEST; CONTROLLED STUDY; CORPUS STRIATUM; DOWN REGULATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; NERVE CELL PLASTICITY; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; GENE EXPRESSION; GENE EXPRESSION PROFILING; METHYLPHENIDATE; PREFRONTAL CORTEX; RATS; RATS, INBRED SHR; RATS, WISTAR; REINFORCEMENT (PSYCHOLOGY); SELF ADMINISTRATION;

EID: 84903731681     PISSN: None     EISSN: 17449081     Source Type: Journal    
DOI: 10.1186/1744-9081-10-17     Document Type: Article

References (60)

1. Heal DJ, Cheetham SC, Smith SL. The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety. Neuropharmacology 2009, 57:608-618.
2. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug addiction in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998, 94:127-152.
3. Kiyatkin EA, Rebec GV. Dopaminergic modulation of glutamate-induced excitations of neurons in the neostriatum and nucleus accumbens of awake, unrestrained rats. J Neurophysiol 1996, 75:142-153.
4. Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 2003, 160:1909-1918.
5. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley J, Wong C, Hitzemann R, Pappas NR. Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D2 receptors. J Pharmacol Exp Ther 1999, 291:409-415.
6. Dalley JW, Theobald D, Cerry JA, Milstein K, Laane BJ, Everitt TW. Cognitive sequelae of intravenous amphetamine self-administration in rats: evidence for selective effects on attentioanal performance. Neuropsychopharmacology 2005, 30:525-537.
7. Fletcher PJ, Korth KM, Stewart J, Chambers JW. Depletion of brain serotonin following intra-raphe injections of 5,7-dihydroxytryptamine does not alter d-amphetamine self-administration across different schedules and access conditions. Psychopharmacology (Berl) 1999, 146:185-193.
8. Marco EM, Adriani W, Ruocco LA, Canese R, Sadile AG, Laviola G. Neurobehavioral adaptations to methylphenidate: The issue of early adolescent exposure. Neurosci Biobehav Rev 2011, 35:1722-1739.
9. Augustyniak PN, Kourrich S, Rezazadeh SM, Stewart J, Arvanitogiannis A. Differential behavioral and neurochemical effects of cocaine after early exposure to methylphenidate in an animal model of attention deficit hyperactivity disorder. Behav Brain Res 2006, 167:379-382.
10. Brandon CL, Marinelli M, White FJ. Adolescent exposure to methylphenidate alters the activity of rat midbrain dopamine neurons. Biol Psychiatry 2003, 54:1338-1344.
11. Harvey RC, Sen S, Deaciuc A, Dwoskin LP, Kantak KM. Methylphenidate treatment in adolescent rats with an attention deficit/hyperactivity disorder phenotype: cocaine addiction vulnerability and dopamine transporter function. Neuropsychopharmacology 2011, 36:837-847.
12. Kollins SH. ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines. J Atten Disord 2008, 12(2):115-125.
13. Soeters HS, Howells FM, Russell VA. Methylphenidate does not increase ethanol consumption in a rat model for attention-deficit hyperactivity disorder-the spontaneously hypertensive rat. Metab Brain Dis 2008, 23:303-314.
14. Steiner H, Van Waes V. Addiction-related gene regulation: risks of exposure to cognitive enhancers vs. other psychostimulants. Prog Neurobiol 2013, 100:60-80.
15. Yuferov V, Nielsen D, Butelman E, Kreek MJ. Microarray studies of psychostimulant-induced changes in gene expression. Addict Biol 2005, 10:101-118.
16. Rhodes JS, Crabbe JC. Gene expression induced by drugs of abuse. Curr Opin Pharmacol 2005, 5(1):26-33.
17. Freeman WM, Lull ME, Patel KM, Brucklacher RM, Morgan D, Roberts D, Vrana KE. Gene expression changes in the medial prefrontal cortex and nucleus accumbens following abstinence from cocaine self-administration. BMC Neurosci 2010, 11:29.
18. Robison AJ, Nestler EJ. Transcriptional and epigenetic mechanisms of addiction. Nat Rev 2011, 12:623-637.
19. Dela Peña IC, Jeon SJ, Lee E, Ryu JH, Shin CY, Noh M, Cheong JH. Neuronal development genes are key elements mediating the reinforcing effects of methamphetamine, amphetamine, and methylphenidate. Psychopharmacology 2013, 230:399-413.
20. Fan X, Bruno KJ, Hess EJ. Rodent models of ADHD. Curr Top Behav Neurosci 2012, 9:273-300.
21. Sagvolden T, Russell VA, Aase H, Johansen EB, Farshbaf M. Rodent models of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005, 57:1239-1247.
22. Russell VA, Sagvolden T, Johansen EB. Animal models of attention-deficit hyperactivity disorder. Behav Brain Funct 2005, 1:9.
23. Sagvolden T. Behavioral validation of the spontaneously hypertensive rat (SHR) as an animal model of attention-deficit/hyperactivity disorder (AD/HD). Neurosci Behav Rev 2000, 24:31-39.
24. Vendruscolo LF, Izidio GS, Takahashi RN. Drug reinforcement in a rat model of attention deficit/hyperactivity disorder. Curr Drug Abuse Rev 2009, 2(2):177-183.
25. Harlan R, Garcia M. Drugs of abuse and immediate-early genes in the forebrain. Mol Neurobiol 1998, 16:221-267.
26. Berke JD, Hyman SE. Addiction, dopamine and the molecular mechanisms of memory. Neuron 2000, 25:515-532.
27. Gerdeman GL, Partridge JG, Lupica CR, Lovinger DM. It could be habit forming: drugs of abuse and striatal synaptic plasticity. Trends Neurosci 2003, 26:184-192.
28. Kalivas PW, Volkow ND. New medications for drug addiction hiding in glutamatergic neuroplasticity. Mol Psychiatry 2011, 16:974-986.
29. Qiu J, Hong Q, Chen RH, Tong ML, Zhang M, Fei L, Pan XQ, Guo M, Guo XR, Chi X. Gene expression profiles in the prefrontal cortex of SHR rats by cDNA microarrays. Mol Biol Rep 2010, 37:1733-1740.
30. Dela Peña IC, Lee JC, Lee HL, Woo TS, Lee HC, Sohn AR, Cheong JH. Differential behavioral responses of the spontaneously hypertensive rat to methylphenidate and methamphetamine: lack of a rewarding effect of repeated methylphenidate treatment. Neurosci Lett 2012, 514:189-193.
31. Kollins SH. A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders. Curr Med Res Opin 2008, 24:1345-1357.
32. Mannuzza S, Klein RG, Truong NL, Moulton JL, Roizen ER, Howell KH. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry 2008, 165:604-609.
33. Gerasimov MR, Franceschi M, Volkow ND, Gifford A, Gatley SJ, Marsteller D, Molina PE, Dewey SL. Comparison between intraperitoneal and oral methylphenidate administration: microdialysis and locomotor activity study. J Pharmacol Exp Ther 2000, 295:51-57.
34. Dela Peña IC, Ahn HS, Choi JY, Shin CY, Ryu JH, Cheong JH. Methylphenidate self-administration and conditioned place preference in an animal model of attention-deficit hyperactivity disorder: the spontaneously hypertensive rat. Behav Pharmacol 2011, 22:31-39. doi:10.1097.
35. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protocols 2008, 4:44-57.
36. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
37. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev 1996, 18:247-291.
38. Dela Peña IC, Cheong JH. Abuse and dependence liability assessment of methylphenidate in the spontaneously hypertensive rat model of attention-deficit/hyperactivity disorder (ADHD): what have we learned?. Arch Pharm Res 2013, 23:400-410.
39. Biederman JJ, Wilens T, Mick E, Faraone SV, Weber W, Curtis S, Thornell A, Pfister K, Jetton J, Soriano J. Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatr 1997, 36:21-29.
40. Yui S, Nakatani Y, Mikami M. Calprotectin (S100a8/S100a9), an inflammatory protein complex from neurophils with a broad apoptosis-inducing activity. Biol Pharm Bull 2003, 26:753-760.
41. Sadasivan S, Pond BB, Pani AK, Qu C, Jiao Y, Smeyne RJ. Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice. PloS One 2012, 7:e33693.
42. Baldwin HA, Colado MI, Murray TK, De Souza RJ, Green AR. Striatal dopamine release in vivo following neurotoxic doses of methamphetamine and effect of the neuroprotective drugs, chlormethiazole and dizolcilpine. Brit J Pharmacol 1993, 108:590-596.
43. Clark KH, Wiley CA, Bradberry CW. Psychostimulant abuse and neuroinflammation: emerging evidence of their interconnection. Neurotox Res 2012, 23:174-188.
44. Filloux F, Townsend JJ. Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection. Exp Neurol 1993, 119:79-88.
45. Hastings TG, Lewis DA, Zigmond MJ. Role of oxidation in the neurotoxic effects of instrastriatal dopamine injections. Proc Natl Acad Sci U S A 1996, 93:1956-1961.
46. Gomes KM, Inacio CG, Valvassori SS, Reus GZ, Boeck CR, Dal-Pizzol F, Quevedo J. Superoxide production after acute and chronic treatment with methylphenidate in young and adult rats. Neurosci Lett 2009, 465(1):95-98.
47. Schmitz F, Scherer EB, da Cunha MJ, da Cunha AA, Lima DD, Delwing D, Netto CA, Wyse AT. Chronic methylphenidate administration alteres antioxidant defenses and butyrylcholinesterase activity in blood of juvenile rats. Mol Cell Biochem 2012, 361:281-288.
48. Chase T, Carrey N, Soo E, Wilkinson M. Methylphenidate regulates activity regulated cytoskeletal associated but not brain-derived neurotrophic factor gene expression in the developing rat striatum. Neuroscience 2007, 144:969-984.
49. Scherer EB, Matte C, Ferreira AG, Gomes KM, Comim CM, Mattos C, Quevedo J, Streck EL, Wyse AT. Methylphenidate treatment increases Na+, K+-ATPase activity in the cerebrum of young and adult rats. J Neural Transm 2009, 116:1681-1687.
50. Scherer EB, da Cunha MJ, Matte C, Schmitz F, Netto C, Wyse AT. Methylphenidate affects memory, brain-derived neurotrophic factor immunocontent and brain acetylcholinesterase activity in the rat. Neurobiol Learn Mem 2010, 94(2):247-253.
51. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology 2010, 35:217-238.
52. Uemura M, Nakao S, Suzuki ST, Takeichi M, Hirano S. OL-protocadherin is essential for growth of striatal axons and thalamocortical projections. Nat Neurosci 2007, 10:1151-1159.
53. Yagi T. Clustered protocadhrin family. Dev Growth Differ 2008, 50(1):S131-S140.
54. Morrow EM, Yoo SY, Flavell SW, Kim TK, Lin Y, Hill RS, Mukaddes NM, Balkhy S, Gascon G, Hashmi A, Al-Saad S, Ware J, Joseph RM, Greenblatt R, Gleason D, Ertelt JA, Apse KA, Bodell A, Partlow JN, Barry B, Yao H, Markianos K, Ferland R, Greenberg ME, Walsch CA. Identifying autism loci and genes by tracing recent shared ancestry. Science 2008, 321:218-223.
55. Sun X, Wang JF, Tseng M, Young LT. Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder. J Psychiatry Neurosci 2006, 31:189-196.
56. Fagundes AO, Scaini G, Santos PM, Sachet MU, Bernhardt NM, Rezin GT, Valvassori SS, Schuck PF, Quevedo J, Streck EL. Inhibition of mitochondrial respiratory chain in the brain of adult rats after acute and chronic administration of methylphenidate. Neurochem Res 2010, 35:405-411.
57. Donovan P, Poronnik P. Nedd4 and Nedd4-2: ubiquitin ligases at work in the neuron. Int J Biochem Cell Biol 2013, 45(3):706-710.
58. Lam YA, Pickart CM, Alban A, Landon M, Jamieson C, Ramage R, Mayer RJ, Layfield R. Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. Proc Natl Acad Sci 2000, 97:9902-9906.
59. Layfield R, Alban A, Mayer RJ, Lowe J. The ubiquitin protein catabolic disorders. Neuropathol Appl Neurobiol 2001, 27:171-179.
60. Fumagalli F, Cattaneo A, Caffino L, Ibba M, Racagni G, Carboni E, Gennarelli M, Riva MA. Sub-chronic exposure to atomoxetine up-regulates BDNF expression and signallin in the brain of adolescent spontaneously hypertensive rats: comparison with methylphenidate. Pharmacol Res 2010, 62(6):523-529.